The PD-1- and LAG-3-targeting Bispecific Molecule Tebotelimab in Solid Tumors and Hematologic Cancers: a Phase 1 Trial
Nature Medicine(2023)
Key words
B-cell lymphoma,Breast cancer,Cancer immunotherapy,Drug development,Ovarian cancer,Biomedicine,general,Cancer Research,Metabolic Diseases,Infectious Diseases,Molecular Medicine,Neurosciences
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined